Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jul 27;11:1689–1703. doi: 10.2147/COPD.S108967

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Ke et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Factors associated with COPD exacerbations within the 12-month postindex period.

Notes: Low FEV₁% predicted defined as FEV₁ <50% predicted; high FEV₁% predicted defined as FEV₁ $50% predicted. Logistic regression was performed with the dependent variable as the occurrence of COPD exacerbations within the 12-month postindex period. Odds ratios and 95% confidence intervals are reported in this figure.

Abbreviations: FEV₁, forced expiratory volume in 1 second; PCP, primary care physician; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long-acting muscarinic agent; SAMA, short-acting muscarinic antagonist; SABA, short-acting (inhaled) β₂-adrenergic agonist; PDE4 inhibitors, phosphodiesterase-4 inhibitors.